|
|
News Breaks
|
November 16, 2009
|
| 07:04 EDT |  | CYTX |
| theflyonthewall.com: | Cytori Therapeutics completes enrollment for RESTORE 2 study | | Cytori Therapeutics completed enrollment in a 70-patient, international breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer. Interim data on the first 32 patients who have reached the six-month follow-up will be presented as a poster at the San Antonio Breast Cancer Symposium December 12, at 7 a.m. U.S. Central Time by Mrs. Eva Weiler-Mithoff, MD, lead investigator at the Glasgow Royal Infirmary. :theflyonthewall.com |
|
|
News For CYTX From The Last 14 Days Check below for free stories on CYTX the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
January 30, 2012
|
| 08:05 EDT | | CYTX |
| theflyonthewall.com: | Cytori receives approval from FDA to initiate U.S. cardiac cell therapy trial | | Cytori Therapeutics has received an Investigational Device Exemption, IDE, approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution® System, an innovative medical device to prepare adipose-derived stem and regenerative cells, ADRCs, to treat a form of coronary heart disease, chronic myocardial ischemia, CMI. The IDE application was originally submitted to the FDA in December 2011. :theflyonthewall.com |
|
|
|
|
|
